Does Medicare Advantage Cover Vardenafil (Levitra/Staxyn)?

How Medicare Advantage Prescription Drug Plans Handle Vardenafil

Medicare Advantage Prescription Drug (MA-PD) plans combine hospital, medical, and drug coverage into a single policy administered by private insurers like UnitedHealthcare, Humana, Aetna, and others. Each plan builds its own formulary under CMS guidelines, which means vardenafil coverage varies by carrier, region, and plan year. The general pattern, though, is consistent: generic vardenafil gets covered, brand Levitra usually does not.

Generic vs. Brand Formulary Placement

Since generic vardenafil entered the U.S. Market in 2018 following patent expiration, most MA-PD plans have dropped brand-name Levitra from their formularies entirely. Generic vardenafil typically sits on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), carrying copays between $15 and $45 per fill. Brand Levitra, when listed at all, lands on Tier 4 (non-preferred brand) with copays of $80 to $150 or coinsurance of 25-50%.

Staxyn, the orally disintegrating tablet formulation, presents a different challenge. Few MA-PD plans include Staxyn on standard formularies. Patients who need the ODT form for swallowing difficulties or convenience will likely need to file a formulary exception request supported by clinical documentation from their prescriber.

CMS Rules That Shape Coverage

CMS requires Part D plans to cover at least two drugs per therapeutic category. For PDE5 inhibitors (the drug class containing vardenafil, sildenafil, tadalafil, and avanafil), this means plans must include at least two options. Most plans satisfy this requirement with generic sildenafil and generic tadalafil, making generic vardenafil an optional but common third inclusion. The FDA-approved prescribing information for vardenafil specifies erectile dysfunction as the sole approved indication, and CMS does not mandate coverage for off-label uses under Part D.

A 2003 key trial by Porst et al. (N=580) demonstrated that vardenafil 20 mg improved erectile function domain scores by 9.3 points on the IIEF versus 3.7 for placebo (P<0.001) [1]. This trial formed part of the clinical evidence package supporting FDA approval and remains a commonly cited reference in formulary committee reviews.

Prior Authorization Requirements for Vardenafil

Roughly 65-75% of MA-PD plans require prior authorization before dispensing vardenafil. The PA process confirms that the prescription targets an FDA-approved indication and that the patient meets plan-specific clinical criteria. Without PA approval, the pharmacy claim will reject at the point of sale.

What Plans Typically Require

Standard PA criteria across major carriers follow a common template. The prescriber must document a confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x), confirm the patient is male and age 18 or older, and verify no contraindicated medications. Concurrent nitrate therapy (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is an absolute contraindication per the FDA label, and plans will deny PA if active nitrate prescriptions appear in the patient's claims history.

Many plans also require documentation that the patient has no untreated cardiovascular conditions that make sexual activity inadvisable. The Princeton III Consensus Guidelines classify patients into low, intermediate, and high cardiovascular risk categories and recommend that high-risk patients be stabilized before initiating PDE5 inhibitor therapy [2].

Turnaround Times

CMS mandates that Part D plans issue standard PA decisions within 72 hours and expedited decisions within 24 hours. In practice, electronic PA (ePA) submissions through platforms like CoverMyMeds or SureScripts often yield decisions within 4 to 8 hours. Paper or fax submissions consistently take longer.

If the PA is denied, the plan must send a written Coverage Determination notice explaining the reason and outlining appeal rights. Keep this notice. You will need it.

Step Therapy: Will You Need to Try Sildenafil First?

Many MA-PD plans enforce step therapy protocols requiring patients to try and fail sildenafil (generic Viagra) before approving vardenafil. The clinical rationale is cost containment: generic sildenafil costs plans $3 to $8 per tablet versus $8 to $20 for generic vardenafil.

How Step Therapy Works in Practice

A step therapy requirement means the plan's system checks your prescription claims history for evidence of a prior sildenafil fill. If no sildenafil claim exists, the vardenafil claim is rejected with a "step therapy" denial code. Your prescriber must then either switch you to sildenafil or submit a step therapy exception documenting why sildenafil is clinically inappropriate.

Valid clinical reasons for bypassing sildenafil step therapy include documented adverse reactions to sildenafil (headache, flushing, visual disturbances), drug interactions with the patient's current regimen, prior treatment failure at adequate doses, or a clinical need for vardenafil's specific pharmacokinetic profile. Vardenafil has a slightly faster median onset (25-30 minutes versus 30-60 minutes for sildenafil) and a duration of approximately 4-5 hours [1].

Pharmacologic Differences That Support Exception Requests

A 2011 meta-analysis published in the Journal of Sexual Medicine (N=4,517 across 11 RCTs) found that while all PDE5 inhibitors show similar overall efficacy rates for erectile dysfunction, individual patient response varies by up to 30-40% between agents [3]. The Endocrine Society's 2018 guidelines on testosterone therapy and erectile dysfunction acknowledge that PDE5 inhibitor switching is appropriate when a first-line agent fails or causes intolerable side effects [4]. Prescribers can cite these data points in step therapy exception requests.

Dr. Arthur Burnett, a professor of urology at Johns Hopkins, has stated: "PDE5 inhibitors are not interchangeable for every patient. Individual pharmacogenomic variation, comorbidity profiles, and concurrent medications all influence which agent works best" [5].

Formulary Tier Placement and Cost Breakdown

Understanding where vardenafil sits on your plan's formulary directly determines your out-of-pocket cost. MA-PD plans use a tiered formulary structure mandated by CMS, and each tier carries different cost-sharing.

Typical Tier Structure for Vardenafil

| Formulary Tier | Drug Form | Typical Copay/Coinsurance | Likelihood | |---|---|---|---| | Tier 1 (Preferred Generic) | Generic vardenafil | $5-$15 | Uncommon | | Tier 2 (Generic) | Generic vardenafil | $15-$45 | Most common | | Tier 3 (Preferred Brand) | Brand Levitra | $45-$80 | Rare | | Tier 4 (Non-Preferred Brand) | Brand Levitra | $80-$150 or 25-50% | If listed at all | | Tier 5 (Specialty) | Staxyn ODT | 25-33% coinsurance | Very rare |

Quantity Limits

Nearly all MA-PD plans impose quantity limits on PDE5 inhibitors. The standard cap is 6 tablets per 30-day fill, though some plans allow up to 12. These limits reflect CMS guidance and historical utilization patterns. If your prescriber writes for a quantity exceeding the plan limit, the pharmacy will need a quantity limit exception approved through the PA process.

Comparing Costs Across Coverage Scenarios

A patient with Tier 2 generic vardenafil coverage and a $20 copay who fills 6 tablets monthly pays $240 annually. The same patient without Part D coverage paying cash at $6 to $8 per generic tablet through discount programs would pay $432 to $576 annually. Medicare Advantage coverage provides meaningful savings for most patients, especially those who fill consistently across the year and reach the coverage gap (donut hole) phase where the manufacturer discount program reduces brand costs by 70%.

According to CMS data for the 2025 plan year, the average Part D beneficiary paid approximately $51 per month in total out-of-pocket prescription costs across all medications [6]. Adding vardenafil at Tier 2 would increase that modestly but should not push most beneficiaries into catastrophic coverage unless they carry high-cost medications in other therapeutic categories.

How to Appeal a Medicare Advantage Denial of Vardenafil

If your MA-PD plan denies coverage for vardenafil, federal regulations guarantee a multi-level appeal process. The denial rate for PDE5 inhibitor coverage on Part D plans runs approximately 15-25% at initial request, but a significant percentage of those denials are overturned on appeal when supported by adequate clinical documentation.

Level 1: Plan Redetermination

File a written appeal with your plan within 60 days of the denial notice. Include a letter of medical necessity from your prescriber, chart notes documenting your ED diagnosis, records of any failed step therapy attempts, and a list of contraindicated alternatives. CMS requires the plan to issue a redetermination within 7 calendar days (72 hours for expedited).

Level 2: Independent Review Entity (IRE)

If the plan upholds the denial, request review by the Independent Review Entity. As of 2026, MAXIMUS Federal Services serves as the IRE for Part D appeals. MAXIMUS operates independently from your plan and reviews the clinical evidence de novo. The IRE must decide within 7 calendar days of receiving the case file.

Level 3 and Beyond

Subsequent appeal levels include an Administrative Law Judge (ALJ) hearing (for claims exceeding $200 in value), the Medicare Appeals Council, and federal district court review. Most vardenafil coverage disputes resolve at Level 1 or Level 2. Only a small fraction proceed to ALJ hearing.

The American Urological Association's 2018 guidelines on erectile dysfunction management state: "PDE5 inhibitors represent first-line pharmacotherapy for ED and should be accessible to patients who meet clinical criteria" [7]. Citing this guideline in appeal letters adds weight to the medical necessity argument.

Vardenafil Coverage for Specific Clinical Scenarios

Not all vardenafil prescriptions receive equal treatment under Medicare Advantage. The clinical indication, formulation, and patient-specific factors all influence whether coverage is approved.

Erectile Dysfunction (Approved Indication)

This is the straightforward scenario. Vardenafil carries FDA approval for erectile dysfunction, and MA-PD plans that include it on formulary will cover it for this diagnosis after PA requirements are met. The prescriber documents ED, confirms no contraindications, and submits the PA. Approval rates for this pathway are high.

Off-Label Uses

Some prescribers write vardenafil off-label for pulmonary arterial hypertension (PAH), Raynaud's phenomenon, or benign prostatic hyperplasia. Part D plans are not required to cover off-label uses unless supported by CMS-recognized compendia (such as the AHFS Drug Information compendium or Micromedex DrugDex). Off-label PA requests require substantially more documentation and are denied at higher rates.

Post-Prostatectomy Erectile Rehabilitation

A growing body of evidence supports early PDE5 inhibitor use following radical prostatectomy to preserve erectile tissue and improve long-term recovery. Montorsi et al. (2008) demonstrated in a randomized trial (N=628) that nightly vardenafil use post-prostatectomy improved IIEF-EF scores compared to on-demand use or placebo at 9 months [8]. Plans may still impose quantity limits, but the clinical rationale for consistent dosing in this population is well established.

Tips for Maximizing Your Coverage

Getting vardenafil covered under Medicare Advantage requires some navigation. These practical steps reduce friction and speed up the process.

Check Your Plan's Formulary Before Your Appointment

Every MA-PD plan publishes its formulary online. Search for "vardenafil" on your plan's drug list before visiting your prescriber. If generic vardenafil is listed, note the tier, quantity limit, PA requirement, and step therapy status. Bring this information to your appointment so your prescriber can write the prescription in a way that matches plan requirements from the start.

Ask Your Prescriber to Use Electronic Prior Authorization

EPA submissions process faster and have higher first-pass approval rates than fax-based requests. Ask your prescriber's office whether they use CoverMyMeds, SureScripts, or a similar ePA platform. If they do, the PA can often be submitted and approved while you are still in the office.

Consider Generic Tadalafil as an Alternative

If your plan covers generic tadalafil at a lower tier than vardenafil, the cost difference may be significant. Tadalafil's 36-hour duration of action offers a different clinical profile that some patients prefer [9]. A 2005 preference study published in European Urology found that 73% of patients who tried both agents had a preference, with the split varying by lifestyle factors and dosing frequency needs [10].

Use the Medicare Plan Finder Tool

The CMS Medicare Plan Finder (medicare.gov) allows you to enter your specific medications and compare formulary coverage, copays, and total estimated annual costs across all MA-PD plans available in your ZIP code. During annual enrollment (October 15 through December 7), this tool can identify plans that cover vardenafil at the lowest out-of-pocket cost.